At Cyclomics, our story begins with a clear mission: to revolutionize cancer diagnostics through innovation in molecular biology and sequencing. Founded in the Netherlands, we are a biotechnology company specializing in advanced molecular diagnostics and DNA sequencing technologies.

​

Our team of scientists and engineers has developed groundbreaking solutions such as CySeq®, our flagship consensus sequencing and liquid biopsy platform, and Epinn®, an AI-driven framework for rapid tumor classification. Together, these technologies empower clinicians and researchers to detect cancer earlier, monitor disease progression, and guide treatment decisions with greater precision and speed.

​

What sets us apart is our dedication to excellence, accuracy, and accessibility. By leveraging cutting-edge sequencing methods, proprietary assays, and AI integration, we transform complex genomic data into actionable insights.

 

Beyond oncology, our technologies extend to plasmid sequencing, methylation analysis, and DNA barcoding, broadening the impact across the life sciences.

​

Driven by our passion for science and our commitment to improving patient outcomes, we continue to push the boundaries of genomic diagnostics. Delivering solutions that make a real difference in healthcare worldwide.